ESC 365 - 24-month results and technical approach of catheter-based renal denervation in patients with resistant hypertension

Back

ESC Premium Access

24-month results and technical approach of catheter-based renal denervation in patients with resistant hypertension

Session: Recent advances in diagnosis/treatment of hypertension

Topic: Device Treatment and Intervention

Speaker: Associate Professor D. Maximkin (Moscow, RU)

Event: ESC Congress 2021 - The Digital Experience

Congress Session

About the speaker

Associate Professor Daniil Maximkin

Peoples Friendship University of Russia (RUDN University), Moscow (Russian Federation)

0 follower

3 more presentations in this session

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

Speaker: Doctor P. Kolkhof (Wuppertal, DE)

Potential therapeutic efficacy via avB3-integrin dependent interaction of developmental endothelial locus-1 (Del-1) after established angiotensin-II dependent hypertension

Speaker: Mr M. Amponsah-Offeh (Dresden, DE)

Protective effects of renal denervation based on MRI assessment of the brain in patients with resistant hypertension

Speaker: Doctor A. Sukhareva (Tomsk, RU)

Access the full session

Recent advances in diagnosis/treatment of hypertension

Speakers: Associate Professor D. Maximkin, Doctor P. Kolkhof, Mr M. Amponsah-Offeh, Doctor A. Sukhareva

Access

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

The long non-coding RNA Heat4 is upregulated in heart failure and decreases the immune response of non-classical monocytes

27 August 2021

ESC Premium Access

The novel ageing-induced long non-coding RNA MIRIAL controls endothelial cell and mitochondrial function

27 August 2021

ESC Premium Access

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

27 August 2021

24-month results and technical approach of catheter-based renal denervation in patients with resistant hypertension

About the speaker

Associate Professor Daniil Maximkin

3 more presentations in this session

Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage

Potential therapeutic efficacy via avB3-integrin dependent interaction of developmental endothelial locus-1 (Del-1) after established angiotensin-II dependent hypertension

Protective effects of renal denervation based on MRI assessment of the brain in patients with resistant hypertension

Access the full session

Recent advances in diagnosis/treatment of hypertension

About the event

ESC Congress 2021 - The Digital Experience

Related content

The long non-coding RNA Heat4 is upregulated in heart failure and decreases the immune response of non-classical monocytes

The novel ageing-induced long non-coding RNA MIRIAL controls endothelial cell and mitochondrial function

Urate lowering therapy is associated with a lower risk of heart failure hospitalisation or mortality in hyperuricaemic patients with heart failure: a comparative effectiveness study

This platform is supported by